Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 70Lymphoma, Large B-Cell, Diffuse 67Lymphoma 66Lymphoma, Follicular 59Leukemia, Lymphocytic, Chronic, B-Cell 58Lymphoma, B-Cell, Marginal Zone 30Burkitt Lymphoma 30Waldenstrom Macroglobulinemia 24Lymphoma, Mantle-Cell 24Lymphoma, B-Cell 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia 19Recurrence 17Hodgkin Disease 12Neoplasms 10Lymphoma, Large-Cell, Immunoblastic 10Multiple Myeloma 8Leukemia, Prolymphocytic 8Leukemia, Myeloid, Acute 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic Syndromes 7Mycosis Fungoides 6Lymphoma, T-Cell, Cutaneous 6Leukemia, Hairy Cell 6Sezary Syndrome 5Neoplasms, Plasma Cell 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, Extranodal NK-T-Cell 5Intraocular Lymphoma 5Dendritic Cell Sarcoma, Interdigitating 5

Interventions

Filgrastim 3Carboplatin 3sodium thiosulfate 2etoposide phosphate 2Radiotherapy 2Cyclophosphamide 2Amifostine 2pegfilgrastim 1glucarpidase 1Triptorelin Pamoate 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Paclitaxel 1Melphalan 1Mannitol 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Cytarabine 1Cisplatin 1Celecoxib 1Capecitabine 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Drug-Related Side Effects and Adverse Reactions × Rituximab × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡